Merck KGaA
Sigma-Aldrich Licenses CRISPR-Cas9 Tech to Horizon Discovery
The deal enables Horizon to support gene editing researchers who need cell-line engineering beyond loss-of-function CRISPR studies into CRISPR-mediated targeted knock-in.
Merck, Burning Rock Ink Liquid Biopsy Companion Diagnostics Deal
The companies intend to develop Burning Rock's 168-gene OncoCompass Target test as a companion to Merck's MET inhibitor Tepmetko in mainland China.
Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko
The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations.
Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China
AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.
AmoyDx Strikes CDx Development Deal for Merck KGaA Cancer Drug
AmoyDx aims to develop a companion diagnostic for Merck KGaA's non-small cell lung cancer treatment Tepmetko, which was recently approved in Japan.